Bitwise leads Solana spot ETFs with $80M in May inflows as Bitcoin and Ethereum bleed capital
While Bitcoin and Ethereum spot ETFs were hemorrhaging capital in May, Solana quietly had its best month in six. US spot Solana ETFs pulled in $115 million in net inflows, with Bitwise’s BSOL fund accounting for roughly $80 million of that total.
Cumulative net inflows into US Solana spot ETFs have now reached approximately $1.13 billion, with Bitwise capturing around 81% of all category flows. Perhaps the most striking detail: May recorded zero outflow days across Solana spot products. Not a single session where more money left than entered.
Bitwise’s BSOL dominance
Bitwise launched BSOL on October 28, 2025, making it the first US spot Solana ETF to hit the market. Seven months later, the fund still commands the lion’s share of inflows in the category.
BSOL includes a built-in staking feature that channels Solana’s average staking rewards of about 7% directly to investors. Bitwise is currently waiving its management fee entirely for the first $1 billion in assets under management.
The rotation story
May’s Solana inflows occurred alongside heavy outflows from both Bitcoin and Ethereum spot ETFs.
What this means for investors
The $1.13 billion in cumulative Solana ETF inflows is still modest compared to Bitcoin’s ETF complex, which measures in the tens of billions.
Bitwise’s fee waiver won’t last forever. Once BSOL crosses $1 billion in AUM, management fees kick in. At the current pace of inflows, that threshold isn’t far off.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs Initiates Tempus AI (TEM.US) with "Neutral" Rating: Diagnostic Business Awaiting Reimbursement Dividends, Data Contracts Enter "Verification Period"
Goldman Sachs has assigned a "Neutral" rating and a $75 price target to Tempus AI; xT and xF reimbursement bonuses are expected, but the sustainability of contracts and competitive advantages with major pharmaceutical companies still needs to be validated.
Inside Strategy’s latest purchase and how $10B in losses turned to $8B in profits!
